Olaparib (PARP inhibitors) – Ovarian Cancer Treatment
In this article, you will find information about the Olaparib (PARP inhibitors), first oral prescription medicine for women with BRCA-mutated advanced ovarian cancer which was approved in 2014.
Ovarian cancer is the sixth most frequent cancer and seventh most prevalent cause of cancer death in women worldwide. PARP (poly (ADP-ribose) polymerase) inhibitors are a unique type of...